Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient

P and T

Volumn 38, Issue 12, 2013, Pages 768-770

  Fadeyi, Michael ^a   Tran, Tin ^b  

^a Outcomes Management   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANAPHYLAXIS; ARTICLE; ASTHMA; BACTERIAL INFECTION; COMMON VARIABLE IMMUNODEFICIENCY; DOSE CALCULATION; DRUG DOSE INCREASE; HEADACHE; HUMAN; IMMUNE DEFICIENCY; INJECTION SITE PAIN; NAUSEA AND VOMITING; SKIN REDNESS;

EID: 84890357646     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Notarangelo LD. Primary immunodefciencies. J Allergy Clin Immunol 2010;125:S182-S194.
2. Bousfha AA, Jeddane L, Mahlaoui N, et al. Primary immunodef-ciency diseases worldwide: More common than generally thought. J Clin Immunol 2013;33(1):1-7.
3. Al-Herz W, Bousfha A, Casanova JL, et al. Primary immuno-deficiency diseases: An update on the classifcation from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011;2:54.
4. Buckley RH. Primary cellular immunodefciencies. J Allergy Clin Immunol 2002;109:747-757.
5. Hall PD, Pilch NW, Atchley DH. Function and evaluation of the immune system (chapter 95). In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy, A Pathophysiologic Approach, 8th ed. New York: McGraw-Hill; 2011;1487.
6. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-728.
7. Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol 2013;33(Suppl 2):S90-S94.
8. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012;169(2):172-181.
9. Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmaco-kinetics of subcutaneous IgPro20 in patients with primary immuno-deficiency. Clin Pharmacokinet 2011;50(6):405-414.
10. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the frst 20% SCIG preparation: A practical approach. Adv Ther 2011;28(7)521-533.
11. Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011;141(1):90-102.
12. Navarro RP, Ballow M, Fenrick B, et al. Considerations for the optimal use of immunoglobulin. Am J Manag Care 2012;18: S67-S78.
13. Eibl M. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28:737-764.
14. Haddad E, Berger M, Wang EC, et al. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol 2012;32:281-289.
15. Roifman CM, Schroeder H, Berger M, et al. Comparison of the Efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune def-ciency: A randomized double-blind trial. Int Immunopharmacol 2003;3:1325-1333.